Tanning
Methodology & AI Transparency ⓘ
Tanning Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Can a tan be healthy? Some people think that tanning gives them a healthy glow.
- 2 Real-world patient consensus: Federal ICD-10-CM code C73.8 categorizes Tanning under Cancer, Oncology & Supportive Care.
- 3 Typical cash cost range: Primary evaluation for Tanning incorporates immunohistochemistry [Tanning C73.8] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Tanning monitoring tracks Comprehensive Metabolic & in Tanning (C73.8: Organ Function Panel) toward Preserved renal/hepatic clearance (C73.8).
Ask our AI Specialists anything about Tanning
What Is Tanning?
Can a tan be healthy? Some people think that tanning gives them a healthy glow. But tanning, either outdoors or indoors with a tanning bed, is not healthy at all. It exposes you to harmful rays and puts you at risk for health problems such as melanoma and other skin cancers . What are UV rays, and how do they affect the skin? Sunlight travels to earth as a mixture of both visible and invisible rays. Some of the rays are harmless to people. But one kind, ultraviolet (UV) rays, can cause problems. They are a form of radiation. UV rays do help your body make vitamin D , but too much exposure damages your skin.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Tanning (C73.8) center on angiogenesis [Tanning C73.8]. Cross-referenced with NIH MeSH (Suntan, Tanning), targeted cancer & oncology interventions aim to normalize Comprehensive Metabolic & in Tanning (C73.8: Organ Function Panel).
Common Symptoms & Clinical Signs
- • Eye damage , including cataracts and photokeratitis (snow blindness)
- • Wear sunglasses that block both UVA and UVB rays. Wrap-around sunglasses work best because they block UV rays from sneaking in from the side
- • Presentation of Tanning (C73.8): abnormality detected early in Tanning (C73.8: on age-appropriate screening)
- • Secondary Tanning clinical sign: persistent painless lump, in Tanning (C73.8: non-healing ulcer/mole change,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Tanning Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C73.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Tanning (C73.8: Organ Function Panel) | Preserved renal/hepatic clearance (C73.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Tanning (C73.8: Genomic Staging) | Guideline-concordant surveillance (C73.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Tanning (C73.8: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C73.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Tanning
Treatment selection for Tanning depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tanning)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Transcriptomic profiling of adjuvant colorectal cancer identifies three key: What a 1,062-Participant Study Found This work furthers our understanding of the underlying biology that propagates stage II/III CRC disease progression and provides scientific rationale for future high-risk stratification and targeted treatment evaluation in... PloS one • 2021-01-15 • Phase III Randomized Trial | N = 1,062 | 90/100 | PMID 34972191 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of cabozantinib for patients with advanced hepatocellular Cabozantinib improved OS and PFS versus placebo in both ALBI grade 1 (hazard ratio [HR] [95% CI]: 0.63 [0.46-0.86] and 0.42 [0.32-0.56]) and ALBI grade 2 (HR [95% CI]: 0.84 [0.66-1.06] and 0.46 [0.37-0.58]) subgroups. British journal of cancer • 2022-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34621044 ↗ |
| New Insights on Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based: What a 554-Participant Study Found Statistical significance for OS was not revealed in. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2021-11-15 • Phase III Randomized Trial | N = 554 | 87/100 | PMID 34265434 ↗ |
| Can This Approach Help? Inside the Latest Research on Adjuvant Chemotherapy for Gastric Cancer may Worsen Prognosis in older adults As this was a post-hoc analysis, the results should be interpreted as hypothesis-generating rather than definitive. Journal of gastrointestinal cancer • 2025-06-27 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40571773 ↗ |
| Can This Approach Help? Inside the Latest Research on Health-related quality of life maintained over time in patients with relapsed or There was no change in patients' health-related quality of life for the first eight cycles of therapy; thereafter, patients treated with daratumumab over the long-term reported improvements in GHS and pain. British journal of haematology • 2021-05-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33555030 ↗ |
Tanning Patient Community & “People Like Me” Threads
Filter Tanning community threads and patient logs by age, biological sex, dosage, and treatment duration.